MedTrace Logo

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts

NCT04788407 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 456

Last updated 2021-07-02

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 500 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in household contacts of patients diagnosed with the disease.

Conditions

Interventions

DRUG

Nitazoxanide

Subjects will receive nitazoxanide 500 mg TID for 7 days

DRUG

Placebo

Subjects will receive placebo TID for 7 days

Sponsors & Collaborators

  • Ministerio de Salud de Ciudad Autónoma de Buenos Aires

    collaborator OTHER_GOV

  • Laboratorios Roemmers S.A.I.C.F.

    collaborator INDUSTRY

  • Fundación Huésped

    lead OTHER

Principal Investigators

  • Omar Sued, MD PhMD · Fundacion Huesped.

  • Herman K Ludvik, MD · Fundación Huésped

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04788407 on ClinicalTrials.gov